CICLOSPORIN for Atopic dermatitis

Inclusion criteria

• {"criterion_text":"- At the moment of giving written informed consent the patient must be between 2-18 y.o.\n- The participant, parent(s)/legal guardian(s) must be willing and give permission to use only one emollient during the clinical trial, provided by the Sponsor.\n- The patient must be vaccinated according to national regulations, the last vaccination at least one month before the first dose of IMP (8 weeks in case of live vaccine). There are no contraindications to vaccination with live vaccines if the patient is in the standard of care arm and 12 weeks after the end of treatment in the arm with CsA and MTX.\n- Diagnosis of moderate or severe AD established at least 6 months before baseline. Moderate-to-severe AD (EASI>16, BSA>10, SCORAD>25) must be confirmed based on clinical features on the screening and baseline visits.\n- The patient, according to doctor’s opinion, is a candidate for systemic therapy.\n- Body weight of the participant is within 3 and 97 percentile grid, matched for sex and age.\n- Female and male participants may be included. The participants who reached sexual maturity must be willing and give permission to use contraceptives or, together with the parent(s)/legal guardian(s), give a written agreement on sexual abstinence for the whole duration of clinical trial and within 6 months after cessation of IMP. In females with childbearing potential (defined as Tanner stage ≥3 or menarche), a pregnancy test must be performed at screening and baseline visit to rule out pregnancy. Pregnancy tests will be performed according to schedule.\n- Within 2 weeks before administration of the first drug dose the patient can use only topical emollients.\n- The participant, parent(s)/legal guardian(s) are willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.\n- The participant, parent(s)/legal guardian(s) give permission to avoid excessive exposure to natural or artificial sunlight (solaria) during the course of clinical trial.\n- The medications taken by the participants because of other causes than AD, must be in stable doses within 2 weeks or 5 half-lives (whichever is longer) prior to the screening visit."}

Exclusion criteria

• {"criterion_text":"- The participant suffers from any acute or chronic disease or has abnormal laboratory tests results which could increase the risk of the trial medical intervention and which, according to the Investigator’s opinion, could interfere with the treatment and obscure the interpretation of the results or which make the subject otherwise ineligible to take part in the clinical trial.\n- Immunosuppressive treatment or use of systemic steroids within 4 weeks before the first dose of IMP.\n- Use of phototherapy within 2 weeks prior to baseline visit or PUVA-therapy within 4 weeks prior to baseline visit.\n- Use of topical steroids or topical calcineurin inhibitors within two weeks before baseline visit.\n- Participation in this and any other clinical trial involving investigational drug(s) within 8 weeks or within 5 half-lives (if known) whichever is longer, prior to clinical trial entry and/or during trial participation.\n- Use of MTX or CsA within 6 months prior to baseline visit.\n- Known or suspected hypersensitivity to any component of the IMP.\n- History of cancer: Subjects who have had any malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.\n- Any disorder which is not stable and in the Investigator’s opinion could: affect the safety of the subject throughout the trial, interfere with the evaluation of the IMP or, impede the subject’s ability to complete the clinical trial. Examples include but are not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, immunological, and psychiatric disorders and major physical impairment.\n- Any abnormal finding which in the Investigator’s opinion may put the subject at risk because of their participation in the trial, influence the results of the trial, influence the subject’s ability to complete the trial.\n- Subjects with strong fear of drawing blood or unwilling to comply with the assessments scheduled during the trial.\n- The presence of any psychiatric disorder, alcohol abuse, drug dependency in the participant or in the participant’s parent(s)/legal guardian(s), which in the Investigator’s opinion may make them unable to take part in the clinical trial and to comply with the trial protocol.\n- Subject or subject’s parent(s)/legal guardian(s) have a language barrier, mental incapacity, unwillingness or lacking ability to understand the trial-related procedures.\n- Subjects who are legally institutionalised.\n- Employees of the Clinical Trial Site or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.\n- Subject who has received any live vaccination within the 8 weeks prior to Baseline Visit. Live vaccines are not allowed during the trial until 12 weeks after last dose IMP.\n- Current clinically significant infection or a history of a clinically significant infection including herpes simplex infection, within 3 months prior to baseline visit which, in the opinion of the Investigator or Sponsor’s medical expert, may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject’s ability to participate in the trial. Clinically significant infections, are defined as: a systemic infection and/or a serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.\n- History of any active skin infection within 1 week prior to baseline visit.\n- Positive test for HIV.\n- Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb may be randomized provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.\n- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0 times the upper limit of normal (ULN) at screening.\n- Immune disorders which may, in the opinion of the Investigator, comprise the safety of the subject in the trial or interfere with evaluation of the IMP.\n- Active or latent tuberculosis or improperly treated tuberculosis, proven with QuantiFERON TB Gold test performed on the screening visit or within 12 weeks before the baseline visit. Chemoprophylaxis in accordance with local guidelines may enable re-screening."}

Primary endpoints

• {"endpoint_text":"- Proportion of patients achieving 75% improvement in EASI (EASI75) from baseline at week 32.","definition_or_measurement_approach":"Proportion of patients achieving 75% improvement in EASI score (EASI75) from baseline measured at week 32."}

Secondary endpoints

• {"endpoint_text":"- Proportion of patients achieving 75% improvement in EASI (EASI75) from baseline at week 16.","definition_or_measurement_approach":"Proportion of patients achieving EASI75 at week 16 compared to baseline."}
• {"endpoint_text":"- Percent change in EASI score from baseline to week 16.","definition_or_measurement_approach":"Percent change in EASI score at week 16 relative to baseline."}
• {"endpoint_text":"- Percent change in EASI score from baseline to week 32.","definition_or_measurement_approach":"Percent change in EASI score at week 32 relative to baseline."}
• {"endpoint_text":"- Proportion of patients with Investigator’s Global Assessment (IGA) 0 (clear) or 1 (almost clear) at week 16.","definition_or_measurement_approach":"Proportion of patients with IGA score 0 or 1 at week 16."}
• {"endpoint_text":"- Proportion of patients with Investigator’s Global Assessment (IGA) 0 (clear) or 1 (almost clear) at week 32.","definition_or_measurement_approach":"Proportion of patients with IGA score 0 or 1 at week 32."}
• {"endpoint_text":"- Change in Scoring Atopic Dermatitis (SCORAD) from baseline to week 16","definition_or_measurement_approach":"Change in SCORAD score at week 16 compared to baseline."}
• {"endpoint_text":"- Change in Scoring Atopic Dermatitis (SCORAD) from baseline to week 32.","definition_or_measurement_approach":"Change in SCORAD score at week 32 compared to baseline."}
• {"endpoint_text":"- Itch Reduction of Pruritus in numeric rating scale (NRS) and in VAS (visual analogue scale) from baseline to Week 16.","definition_or_measurement_approach":"Change in pruritus measured by NRS and VAS at week 16 versus baseline."}
• {"endpoint_text":"- Itch Reduction of Pruritus in numeric rating scale (NRS) and in VAS (visual analogue scale) from baseline to Week 32.","definition_or_measurement_approach":"Change in pruritus measured by NRS and VAS at week 32 versus baseline."}
• {"endpoint_text":"- Change in Children’s Dermatology Life Quality Index (CDLQI) score from baseline to Week 16.","definition_or_measurement_approach":"Change in CDLQI score at week 16 relative to baseline."}
• {"endpoint_text":"- Change in Children’s Dermatology Life Quality Index (CDLQI) score from baseline to Week 32","definition_or_measurement_approach":"Change in CDLQI score at week 32 relative to baseline."}
• {"endpoint_text":"- Change in Family Dermatology Life Quality Index (FDQL) from baseline to week 16.","definition_or_measurement_approach":"Change in FDQL at week 16 versus baseline."}
• {"endpoint_text":"- Change in Family Dermatology Life Quality Index (FDQL) from baseline to week 32.","definition_or_measurement_approach":"Change in FDQL at week 32 versus baseline."}
• {"endpoint_text":"- Change in Infant’s Dermatitis Quality of Life (IDQI) from baseline to week 16.","definition_or_measurement_approach":"Change in IDQI at week 16 versus baseline."}
• {"endpoint_text":"- Change in Infant’s Dermatitis Quality of Life (IDQI) from baseline to week 32.","definition_or_measurement_approach":"Change in IDQI at week 32 versus baseline."}
• {"endpoint_text":"- Change in Patient-Oriented Eczema Measure (POEM) from baseline to week 16.","definition_or_measurement_approach":"Change in POEM score at week 16 compared to baseline."}
• {"endpoint_text":"- Change in Patient-Oriented Eczema Measure (POEM) from baseline to week 32.","definition_or_measurement_approach":"Change in POEM score at week 32 compared to baseline."}
• {"endpoint_text":"- Incidence of treatment-emergent AE from baseline through week 16.","definition_or_measurement_approach":"Incidence (frequency) of treatment-emergent adverse events from baseline to week 16."}
• {"endpoint_text":"- Incidence of treatment-emergent AE from baseline through week 32.","definition_or_measurement_approach":"Incidence (frequency) of treatment-emergent adverse events from baseline to week 32."}
• {"endpoint_text":"- Incidence of treatment-emergent AE leading to treatment discontinuation from baseline through week 16.","definition_or_measurement_approach":"Incidence of treatment-emergent adverse events leading to discontinuation from baseline to week 16."}
• {"endpoint_text":"- Incidence of treatment-emergent AE leading to treatment discontinuation from baseline through week 32.","definition_or_measurement_approach":"Incidence of treatment-emergent adverse events leading to discontinuation from baseline to week 32."}
• {"endpoint_text":"- Time to exacerbation of AD (loss of at least 50% of the EASI response at week 32) after treatment cessation at week 32.","definition_or_measurement_approach":"Time to exacerbation defined as loss of at least 50% of the EASI response achieved at week 32 after treatment cessation at week 32."}

Poland

Earliest CTIS Part Ii Submission Date

21-10-2024

Latest Decision Or Authorization Date

02-12-2024

Processing Time Days

42

Number Of Sites

1

Number Of Participants

317

Primary sponsor

Full Name

Medical University Of Lodz

Organisation Type

Educational Institution

Country Of Registered Address

Poland